FDA recommends repeat dosing of COVID-19 monoclonal antibody

The Food & Drug Administration last week revised its Evusheld fact sheet for health care providers, recommending repeat dosing every six months if patients need ongoing protection. The FDA said data and modeling suggest that antiviral activity against the currently circulating SARS-CoV-2 variants and subvariants may be retained for six months at drug concentrations achieved following an Evusheld dose of 300 mg of tixagevimab and 300 mg cilgavimab. The previous fact sheet did not provide a specific recommendation on the dosing interval.